Breast Cancer

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, discusses how nurses can help their patients.

Pain in patients with breast cancer who have had surgery or who have late-stage disease is common, and managing it effectively can be difficult.

Women with HR-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent- tamoxifen compared with standard tamoxifen alone, according to results from the phase III SOFT trial.

Erin W. Hofstatter, MD, assistant professor of medicine (medical oncology), co-director, Genetic Counseling Program, Yale Cancer Center, discusses chemoprevention to reduce one's risk of developing breast cancer.

This portion will discuss the conceptualization of health in rural areas and barriers to accessing healthcare.

The big difference in progression-free survival seen in pivotal trial data propelled palbociclib to its accelerated FDA approval for the treatment of metastatic breast cancer, bringing with it the potential for the drug to quickly become adapted as the new standard of care, Brian Wojciechowski, MD, said.

Jack Cuzick, PhD, a professor of epidemiology at Wolfson Institute of Preventive Medicine, discusses how to determine if a woman is at high risk of developing breast cancer and which of these women should consider taking tamoxifen as a preventative measure.

Women diagnosed with early-stage breast disease have a variety of decisions to make regarding their treatment options. For example, some women may be eligible for breast-conserving surgery, which typically includes a lumpectomy followed by radiation.

Jean Weigert, MD, head of breast imaging for the Hospital of Central Connecticut, discusses a study conducted in Connecticut to see if the addition of screening breast ultrasound in women with mammographically normal but dense breasts has increased breast cancer detection.

A new study has found that while the breast cancer prevention drug tamoxifen's benefits outweigh its risks, the drug isn't right for all women.

Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference (MBCC).

Joan Lunden discusses the diagnostic approach that led to the early detection of triple-negative breast cancer, which was undetected by mammogram and 3D mammogram but was detected with ultrasound.

Each year, the American Cancer Society publishes its annual cancer statistics, highlighting gains as well as areas that need continued focus. For 2015, the organization's report shows a 22% decrease in cancer death over the past 20 years, equating to more than 1.5 million lives saved-a positive trend seen for the past few years.

Jessica Goldberg, MSN, adult gerontology nurse practitioner, fellow in palliative medicine, Memorial Sloan Kettering Cancer Center, discusses the results of a study in which a cancer self-management intervention was created for patients with breast cancer.

Rowan Chlebowski, MD, PhD, Professor and Chief, Harbor-UCLA Medical Center, Department of Internal Medicine, Medical Oncology/Hematology Member, Jonsson Comprehensive Cancer Center, discusses the results of the Women's Intervention Nutrition Study (WINS).

Protective effect of tamoxifen continues after treatment stops.

Erin W. Hofstatter, MD, assistant professor of medicine (medical oncology), co-director, Genetic Counseling Program, Yale Cancer Center, explains why it is important for breast cancer survivors to maintain a healthy lifestyle after their treatment

A new study has shown that postmenopausal women who had insulin abnormalities were at an increased risk for breast cancer regardless if they were overweight or normal-weight individuals.

Anees B. Chagpar, MD, MSc, MA, MPH, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, program director, Interdisciplinary Breast Fellowship, assistant director, Diversity and Health Equity at Yale Cancer Center, explains how lifestyle changes that align with the US Cancer Prevention Guidelines can reduce one's breast cancer risk.

Results of a phase II study showed that women with small, stage I HER2-positive tumors who received a combination of lower-intensity chemotherapy and the targeted drug trastuzumab following surgery were highly unlikely to have the cancer recur within 3 years

Two recent studies outline the importance of nutrition in preventing obesity-related cancers as well as the potential benefits of a nutrition education intervention in preventing breast cancer recurrence.

Rowan Chlebowski, MD, PhD, discusses how losing 5 pounds, as seen in the Women's Intervention Nutrition Study, had a positive impact for breast cancer patients, especially whose disease was triple-negative.

Results of a large retrospective study of more than 20,000 women treated for early-stage breast cancer are shedding light on how much treatment may be too much for these early-stage cancers.

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing. In the past 18 months, the floodgates for testing options have opened, as companies seek to enter the diagnostic market in the wake of the US Supreme Court's June 2013 ruling that "naturally occurring" human genes are a "product of nature" and cannot be patented, breaking Myriad Genetics' monopoly on BRCA1/2 gene testing.

Anees B. Chagpar, MD, MSc, MA, MPH, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, program director, Interdisciplinary Breast Fellowship, assistant director, Diversity and Health Equity at Yale Cancer Center, discusses a study that looked at patient perceptions of the impact of genetic testing for breast cancer risk on health insurance.